P435 Management of iron deficiency in inflammatory bowel disease: results from a RAND/UCLA appropriateness study
Walter Reinisch(Medical University of Vienna), Herman Stoevelaar(Barnes-Jewish Hospital), Fernando Gomollón(Universidad de Zaragoza), Bjørn Moum(University of Oslo), Axel Dignaß(Goethe University Frankfurt), Silvio Danese(IRCCS Ospedale San Raffaele), Yehuda Chowers(Cleveland Clinic), Péter L. Lakatos(McGill University), Murat Törüner(Ankara University), G. Mantzaris(Evangelismos Hospital), Charlie W. Lees(Western General Hospital), C. Janneke van der Woude(Radboud University Nijmegen), Pierre Michetti, Stefan Lindgren(Skåne University Hospital), Ole Haagen Nielsen(University of Copenhagen)
Cited by 0
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k